FREDERICK, MD, Aug. 20, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com, is pleased to announce that it has filed a 510(k), Premarket Notification application with the U.S. Food and Drug Administration (FDA). The application is to seek expanded market clearance for the drug free, over-the-counter ActiPatch® Musculoskeletal Pain Therapy medical … Continue Reading
The Stock Day Podcast Hosts BioElectronics’ to Discuss Its New Technology To Mitigate Opioid Use
PHOENIX, AZ / ACCESSWIRE / July 10, 2019 / The Stock Day Podcast welcomed BioElectronics Corporation (BIEL) (“the Company”), a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices. Vice President of Sales, Keith Nalepka, joined Stock Day host Everett Jolly. Jolly began the interview by asking … Continue Reading
BioElectronics Announces FDA Market Clearance for Its Non-Opioid Postoperative Pain Therapy
FREDERICK, MD, July 01, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com, the maker of non-invasive electroceutical devices, is pleased to announce that it has received market clearance from the United States Food and Drug Administration (US FDA) for its RecoveryRx® medical device, for the treatment of postoperative pain. Physicians are … Continue Reading
BioElectronics Announces Publication of Study Verifying the Effectiveness of Its ActiPatch Medical Device on Chronic Pain
FREDERICK, MD, June 03, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC PINK: BIEL) www.bielcorp.com, the maker of non-invasive electroceutical devices, is pleased to announce the publication of a registry study in the May 2019 edition of the Journal of Pain Management. Titled “Chronic pain intervention using pulsed shortwave therapy: the relationship between … Continue Reading
BioElectronics Announces Withdrawal and Planned Resubmission of 510(k) for General Musculoskeletal Pain
FREDERICK, MD, May 22, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC PINK: BIEL) www.bielcorp.com, the maker of non-invasive electroceutical devices, announced today that it has voluntarily withdrawn its 510(k) application for “over-the-counter adjunctive treatment of musculoskeletal pain in women” to the U.S. Food and Drug Administration (FDA), due to the availability of data … Continue Reading
BioElectronics Responds to FDA’s 510(k) Additional Information Requests for its Musculoskeletal Pain Relief and Postoperative Pain Applications
FREDERICK, MD, April 23, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com announced that the Company has submitted its response to the U.S. Food and Drug Administration’s (FDA) request for additional information on its ActiPatch® 510(k) market clearance application for “treatment of musculoskeletal pain in women”. Additionally, the Company has … Continue Reading
Northwest Specialty Hospital Now Offering Electroceutical Alternative To Opioids In Clinical Practice
PR Newswire POST FALLS, Idaho, March 14, 2019 POST FALLS, Idaho, March 14, 2019 /PRNewswire/ — Northwest Specialty Hospital is proud to announce that they are offering electroceutical devices as an alternative to opioid medication for pain management in conjunction with RiversEdge Orthopedics, Axis Spine and Bioelectronics Corporation (OTC PINK: BIEL). According to the National Institute on Drug Abuse, … Continue Reading
BioElectronics Announces Back Pain Clinical Study with Leading Australian Pain Center
Pulsed Shortwave Neuromodulation Therapy (ActiPatch®) Study in Chronic Lower Back Pain FREDERICK, MD, March 08, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC PINK: BIEL) http://www.bielcorp.comis pleased to announce the commencement of a clinical study investigating the efficacy of ActiPatch in treating chronic lower back pain. The objectives of this additional back pain study are … Continue Reading
BioElectronics Files FDA Applications for Treatment of Musculoskeletal & Postoperative Pain
FREDERICK, MD, Feb. 12, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that two Traditional 510(k) Premarket Notification applications were filed with the U.S. Food and Drug Administration (FDA). The applications were for the ActiPatch® and RecoveryRx® medical devices for market clearances of “over-the-counter adjunctive treatment of musculoskeletal … Continue Reading
President’s Response to Stock Price Decline
Frederick, Maryland, Dec. 04, 2018 (GLOBE NEWSWIRE) – Dear Fellow Shareholders: While we were all disappointed by the dramatic drop in the stock price, it hasn’t had an impact on the Company’s operations. What is still needed is a cost-effective efficacious painkiller that is also an alternative to opioids. Physicians prescribe, and patients take opioids … Continue Reading